EMA · European Union
rimonabant — EMA regulatory status
rimonabant (ZIMULTI) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA withdrawn.
Status snapshot
- Status
- EMA withdrawn
- Brand
- ZIMULTI
- Mechanism
- Cannabinoid CB1 receptor antagonist
- Target
- Cannabinoid receptor 1
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Cannabinoid CB1 receptor antagonist. Target: Cannabinoid receptor 1. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: withdrawn.
Linked evidence on this spoke: 2 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | withdrawn | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Rimonabant | Phase 3 | Sanofi Pasteur MSD | NCT00478972 |
| Rimonabant | Phase 2 | BRIGHT MINDS BIOSCIENCES | NCT00547118 |
Related hubs
FAQ
What is the EMA approval status of rimonabant?
rimonabant currently shows EMA withdrawn in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get rimonabant regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to rimonabant?
This spoke lists 2 published programs associated with rimonabant in our pipeline index.